AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M
AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M
AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.